Apolipoprotein M: Bridging HDL and endothelial function

Current Opinion in Lipidology

Volumn 24, Issue 4, 2013, Pages 295-300

  Christoffersen, Christina ^a   Nielsen, Lars Bo ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Department of Biomedical Science ^*  (Denmark)

Author keywords

Apolipoprotein M; Endothelium; Lipocalins; Sphingosine 1 phosphate

Indexed keywords

APOLIPOPROTEIN M; FINGOLIMOD; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOCALIN; PHOSPHOLIPID; PHOSPHOTRANSFERASE INHIBITOR; RETINOIC ACID; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; BIOLOGICAL ACTIVITY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; HUMAN; LIGAND BINDING; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; LUNG ENDOTHELIUM; NONHUMAN; OXIDATION; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; REVIEW; SEPSIS; VASCULAR ENDOTHELIUM;

ANIMALS; APOLIPOPROTEINS; ATHEROSCLEROSIS; ENDOTHELIAL CELLS; HUMANS; LIPID METABOLISM; LIPOCALINS; LIPOPROTEINS, HDL; LYSOPHOSPHOLIPIDS; PROTEIN BINDING; SEPSIS; SPHINGOSINE;

MUS;

EID: 84880595495     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0b013e328361f6ad     Document Type: Review

References (57)

1. Ishii I, Fukushima N, Ye X, Chun J. Lysophospholipid receptors: signaling and biology. Annu Rev Biochem 2004; 73:321-354.
2. English D, Welch Z, Kovala AT, et al. Sphingosine 1-phosphate released from platelets during clotting accounts for the potent endothelial cell chemotactic activity of blood serum and provides a novel link between hemostasis and angiogenesis. FASEB J 2000; 14:2255-2265.
3. Du W, Takuwa N, Yoshioka K, et al. S1P(2), the G protein-coupled receptor for sphingosine-1-phosphate, negatively regulates tumor angiogenesis and tumor growth in vivo in mice. Cancer Res 2010; 70:772-781.
4. Lee MJ, Thangada S, Claffey KP, et al. Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate. Cell 1999; 99:301-312.
5. Wilkerson BA, Grass GD, Wing SB, et al. Sphingosine 1-phosphate (S1P) carrier-dependent regulation of endothelial barrier: high density lipoprotein (HDL)-S1P prolongs endothelial barrier enhancement as compared with albumin-S1P via effects on levels, trafficking, and signaling of S1P1. J Biol Chem 2012; 287:44645-44653.
6. Pappu R, Schwab SR, Cornelissen I, et al. Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science 2007; 316:295-298.
7. Christoffersen C, Obinata H, Kumaraswamy SB, et al. Endothelium- protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M. Proc Natl Acad Sci U S A 2011; 108:9613-9618.
8. Xu N, Dahlback B. A novel human apolipoprotein (apoM). J Biol Chem 1999; 274:31286-31290.
9. Duan J, Dahlback B, Villoutreix BO. Proposed lipocalin fold for apolipoprotein M based on bioinformatics and site-directed mutagenesis. FEBS Lett 2001; 499:127-132.
10. Flower DR. The lipocalin protein family: structure and function. Biochem J 1996; 318 (Pt 1):1-14.
11. Sevvana M, Ahnstrom J, Egerer-Sieber C, et al. Serendipitous fatty acid binding reveals the structural determinants for ligand recognition in apolipoprotein M. J Mol Biol 2009; 393:920-936.
12. Schlehuber S, Skerra A. Lipocalins in drug discovery: from natural ligandbinding proteins to 'anticalins'. Drug Discov Today 2005; 10:23-33.
13. Axler O, Ahnstrom J, Dahlback B. Apolipoprotein M associates to lipoproteins through its retained signal peptide. FEBS Lett 2008; 582:826-828.
14. Christoffersen C, Ahnstrom J, Axler O, et al. The signal peptide anchors apolipoprotein M in plasma lipoproteins and prevents rapid clearance of apolipoprotein M from plasma. J Biol Chem 2008; 283:18765-18772.
15. Raper J, Fung R, Ghiso J, et al. Characterization of a novel trypanosome lytic factor from human serum. Infect Immun 1999; 67:1910-1916.
16. Sorenson RC, Bisgaier CL, Aviram M, et al. Human serum Paraoxonase/Arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids: apolipoprotein A-I stabilizes activity. Arterioscler Thromb Vasc Biol 1999; 19:2214-2225.
17. Segrest JP, Jones MK, De LH, et al. The amphipathic helix in the exchangeable apolipoproteins: a review of secondary structure and function. J Lipid Res 1992; 33:141-166.
18. Eichinger A, Nasreen A, Kim HJ, Skerra A. Structural insight into the dual ligand specificity and mode of high density lipoprotein association of apolipoprotein D. J Biol Chem 2007; 282:31068-31075.
19. Davidson WS, Silva RA, Chantepie S, et al. Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: relevance to antioxidative function. Arterioscler Thromb Vasc Biol 2009; 29:870-876.
20. Axler O, Ahnstrom J, Dahlback B. An ELISA for apolipoprotein M reveals a strong correlation to total cholesterol in human plasma. J Lipid Res 2007; 48:1772-1780.
21. Christoffersen C, Nielsen LB, Axler O, et al. Isolation and characterization of human apolipoprotein M-containing lipoproteins. J Lipid Res 2006; 47: 1833-1843.
22. Christoffersen C, Jauhiainen M, Moser M, et al. Effect of apolipoprotein M on high density lipoprotein metabolism and atherosclerosis in low density lipoprotein receptor knock-out mice. J Biol Chem 2008; 283:1839-1847.
23. Wolfrum C, Poy MN, Stoffel M. Apolipoprotein M is required for prebeta-HDL formation and cholesterol efflux to HDL and protects against atherosclerosis. Nat Med 2005; 11:418-422.
24. Christoffersen C, Pedersen TX, Gordts PL, et al. Opposing effects of apolipoprotein m on catabolism of apolipoprotein B-containing lipoproteins and atherosclerosis. Circ Res 2010; 106:1624-1634.
25. Bektas M, Allende ML, Lee BG, et al. Sphingosine 1-phosphate lyase deficiency disrupts lipid homeostasis in liver. J Biol Chem 2010; 285:10880-10889.
26. Christoffersen C, Benn M, Christensen PM, et al. The plasma concentration of HDL-associated apoM is influenced by LDL receptor-mediated clearance of apoB-containing particles. J Lipid Res 2012; 53:2198-2204.
27. Flower DR, North AC, Sansom CE. The lipocalin protein family: structural and sequence overview. Biochim Biophys Acta 2000; 1482:9-24.
28. Flower DR. Multiple molecular recognition properties of the lipocalin protein family. J Mol Recognit 1995; 8:185-195.
29. Ahnstrom J, Faber K, Axler O, Dahlback B. Hydrophobic ligand binding properties of the human lipocalin apolipoprotein M. J Lipid Res 2007; 48:1754-1762.
30. Elsoe S, Ahnstrom J, Christoffersen C, et al. Apolipoprotein M binds oxidized phospholipids and increases the antioxidant effect of HDL. Atherosclerosis 2012; 221:91-97.
31. Faber K, Axler O, Dahlback B, Nielsen LB. Characterization of apoM in normal and genetically modified mice. J Lipid Res 2004; 45:1272-1278.
32. Sevvana M, Kassler K, Ahnstrom J, et al. Mouse ApoM displays an unprecedented seven-stranded lipocalin fold: folding decoy or alternative native fold? J Mol Biol 2010; 404:363-371.
33. Cogan U, Kopelman M, Mokady S, Shinitzky M. Binding affinities of retinol and related compounds to retinol binding proteins. Eur J Biochem 1976; 65:71-78.
34. Scherer M, Schmitz G, Liebisch G. High-throughput analysis of sphingosine 1-phosphate, sphinganine 1-phosphate, and lysophosphatidic acid in plasma samples by liquid chromatography-tandem mass spectrometry. Clin Chem 2009; 55:1218-1222.
35. Murata N, Sato K, Kon J, et al. Interaction of sphingosine 1-phosphate with plasma components, including lipoproteins, regulates the lipid receptormediated actions. Biochem J 2000; 352 (Pt 3):809-815.
36. Karuna R, Park R, Othman A, et al. Plasma levels of sphingosine-1- phosphate and apolipoprotein M in patients with monogenic disorders of HDL metabolism. Atherosclerosis 2011; 219:855-863.
37. Zhang B, Tomura H, Kuwabara A, et al. Correlation of high density lipoprotein (HDL)-associated sphingosine 1-phosphate with serum levels of HDL-cholesterol and apolipoproteins. Atherosclerosis 2005; 178:199-205.
38. Teijaro JR, Walsh KB, Cahalan S, et al. Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection. Cell 2011; 146:980-991.
39. Zhao Y, Gorshkova IA, Berdyshev E, et al. Protection of LPS-induced murine acute lung injury by sphingosine-1-phosphate lyase suppression. Am J Respir Cell Mol Biol 2011; 45:426-435.
40. Szczepaniak WS, Zhang Y, Hagerty S, et al. Sphingosine 1-phosphate rescues canine LPS-induced acute lung injury and alters systemic inflammatory cytokine production in vivo. Transl Res 2008; 152:213-224.
41. Bachmaier K, Guzman E, Kawamura T, et al. Sphingosine kinase 1 mediation of expression of the anaphylatoxin receptor C5L2 dampens the inflammatory response to endotoxin. PLoS One 2012; 7:e30742.
42. Fyrst H, Saba JD. An update on sphingosine-1-phosphate and other sphingolipid mediators. Nat Chem Biol 2010; 6:489-497.
43. Camerer E, Regard JB, Cornelissen I, et al. Sphingosine-1-phosphate in the plasma compartment regulates basal and inflammation-induced vascular leak in mice. J Clin Invest 2009; 119:1871-1879.
44. Hanson MA, Roth CB, Jo E, et al. Crystal structure of a lipidG protein-coupled receptor. Science 2012; 335:851-855.
45. Poti F, Bot M, Costa S, et al. Sphingosine kinase inhibition exerts both proand antiatherogenic effects in low-density lipoprotein receptor-deficient (LDL-R((/()) mice. Thromb Haemost 2012; 107:552-561.
46. Skoura A, Michaud J, Im DS, et al. Sphingosine-1-phosphate receptor-2 function in myeloid cells regulates vascular inflammation and atherosclerosis. Arterioscler Thromb Vasc Biol 2011; 31:81-85.
47. Keul P, Lucke S, von Wnuck LK, et al. Sphingosine-1-phosphate receptor 3 promotes recruitment of monocyte/macrophages in inflammation and atherosclerosis. Circ Res 2011; 108:314-323.
48. Nofer JR, Bot M, Brodde M, et al. FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 2007; 115:501-508.
49. Keul P, Tolle M, Lucke S, et al. The sphingosine-1-phosphate analogue FTY720 reduces atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2007; 27:607-613.
50. Klingenberg R, Nofer JR, Rudling M, et al. Sphingosine-1-phosphate analogue FTY720 causes lymphocyte redistribution and hypercholesterolemia in Apo Edeficient mice. Arterioscler Thromb Vasc Biol 2007; 27:2392-2399.
51. Ahnstrom J, Axler O, Jauhiainen M, et al. Levels of apolipoprotein M are not associated with the risk of coronary heart disease in two independent casecontrol studies. J Lipid Res 2008; 49:1912-1917.
52. Sattler KJ, Elbasan S, Keul P, et al. Sphingosine 1-phosphate levels in plasma and HDL are altered in coronary artery disease. Basic Res Cardiol 2010; 105:821-832.
53. Argraves KM, Sethi AA, Gazzolo PJ, et al. S1P, dihydro-S1P and C24: 1-ceramide levels in the HDL-containing fraction of serum inversely correlate with occurrence of ischemic heart disease. Lipids Health Dis 2011; 10:70.
54. van Leeuwen HJ, Heezius EC, Dallinga GM, et al. Lipoprotein metabolism in patients with severe sepsis. Crit Care Med 2003; 31:1359-1366.
55. Gupta H, Dai L, Datta G, et al. Inhibition of lipopolysaccharide-induced inflammatory responses by an apolipoprotein AI mimetic peptide. Circ Res 2005; 97:236-243.
56. Berbee JF, van der Hoogt CC, Kleemann R, et al. Apolipoprotein CI stimulates the response to lipopolysaccharide and reduces mortality in gram-negative sepsis. FASEB J 2006; 20:2162-2164.
57. Kumaraswamy SB, Linder A, Akesson P, Dahlback B. Decreased plasma concentrations of apolipoprotein M in sepsis and systemic inflammatory response syndromes. Crit Care 2012; 16:R60.